Sarcopenia is one of the quiet epidemics of an aging world. It is diagnosed when both muscle strength and muscle quantity fall below defined thresholds, and it predicts falls, fractures, hospitalization, and death. Yet the biology behind it remains only partly understood. Most research has focused on neuromuscular decline, protein metabolism, chronic inflammation, and inactivity. The new study turns attention to a less obvious suspect: the network of tiny blood vessels that feeds muscle tissue, and the molecular signals that build and maintain that network.

Angiogenesis — the sprouting of new capillaries from existing vessels — is essential to muscle health. Every muscle fiber depends on a dense microcirculation to deliver oxygen, glucose, amino acids, and hormones, and to clear metabolic waste. When a muscle is injured, new vessel formation is one of the earliest events in repair, preceding the regeneration of the muscle fibers themselves. As people age, capillary density in skeletal muscle falls, a process called capillary rarefaction, and the decline is most pronounced around the fast-twitch type II fibers that sarcopenia strips away first. Human biopsy studies have linked this vascular thinning directly to weaker grip, smaller appendicular muscle mass, and poorer physical performance.

The research team, led by Hui Li and Feng Jia of Nanyang Central Hospital together with colleagues at the Seventh People’s Hospital of Zhengzhou, measured three serum angiogenesis markers using enzyme-linked immunosorbent assays: VEGF, the master driver of new vessel growth; ANGPT1, which stabilizes and matures vessels; and ANGPT2, which antagonizes ANGPT1 and promotes vessel remodeling. Fasting blood samples were drawn the morning after admission, processed under standardized conditions, stored at minus 80 degrees Celsius, and assayed in duplicate by laboratory staff blinded to each patient’s clinical status. Quality controls kept measurement variability below 10 percent within assays and below 15 percent between batches spread across five years.

Sarcopenia was defined according to the Asian Working Group for Sarcopenia criteria, requiring both reduced hand grip strength and reduced appendicular skeletal muscle mass. Grip was tested with a calibrated dynamometer in a standardized seated posture, three trials per hand, with the best value recorded. Muscle mass was estimated by multi-frequency bioimpedance analysis using an eight-frequency device that measured each limb separately, performed after an overnight fast with strict controls for hydration status. Of the 471 participants, 68 — or 14.44 percent — met the criteria for sarcopenia.

The results were striking in their consistency. Patients with sarcopenia had significantly lower VEGF — an average of 116.95 picograms per milliliter versus 138.60 in those without the condition — and dramatically lower ANGPT1, at 23.68 nanograms per milliliter versus 34.15. ANGPT2, by contrast, showed no meaningful difference. In regression models adjusted first for age, sex, and body mass index, and then further for comorbidity burden, hemoglobin, albumin, smoking, alcohol use, and hypertension, VEGF remained positively correlated with both grip strength and muscle mass, while ANGPT1 held its association with muscle mass and, in the fully adjusted model, with grip strength as well.

The risk statistics are the headline numbers. Using receiver operating characteristic analysis, the team derived cutoff values — VEGF at or below 102.55 picograms per milliliter and ANGPT1 at or below 19.47 nanograms per milliliter — and validated them with ten-fold cross-validation to guard against overestimation. In fully adjusted logistic models, low VEGF was associated with roughly a threefold higher odds of sarcopenia (odds ratio 3.360), and low ANGPT1 with even greater odds (3.709, p < 0.001). Among patients with low ANGPT1, more than a quarter — 25.55 percent — had sarcopenia, compared with fewer than 10 percent of those with normal levels. Adding either marker to a base clinical model built from age, sex, BMI, comorbidities, and routine labs significantly improved the model’s statistical fit, with ANGPT1 delivering the largest gain.

Why would vessel-building signals track so closely with failing muscle? The authors propose a dual-hit mechanism rooted in the aging muscle’s microenvironment. Endothelial cells and satellite cells — the stem cells that rebuild muscle — sit side by side and exchange chemical messages. VEGF acts directly on satellite cell receptors to trigger their activation, proliferation, and migration after injury; ANGPT1 then supports their survival and coordinates their differentiation and fusion into mature, multinucleated muscle fibers. When circulating VEGF and ANGPT1 both fall, the regenerative sequence is disrupted at both ends: the vascular supply shrinks and the stem cell pipeline stalls, leaving chronic micro-injuries to heal poorly — the hallmark of sarcopenic muscle. Animal work supports the plausibility: VEGF gene delivery improves muscle ischemia and repair in rodents, and ANGPT1 enhances regeneration in mice, while exercise and even massage raise VEGF expression in skeletal muscle.

The study’s limitations deserve equal billing. It is cross-sectional, so it cannot say whether low angiogenic markers cause muscle loss or simply reflect it — reverse causation remains a real possibility. Serum VEGF and ANGPT1 are systemic signals, not direct measurements of the muscle microenvironment, and their blood levels can be swayed by subclinical disease, inflammation, nutrition, and activity. The cohort was drawn from a single hospital’s gastroenterology and general surgery service rather than the community, and physical performance testing was unavailable, preventing severity grading. The diagnostic discrimination of the markers alone was modest — area under the curve of 0.641 for VEGF and 0.668 for ANGPT1 — meaning they add incremental value to clinical assessment rather than replacing it. ANGPT2, notably, contributed nothing once confounders were accounted for.

Even with those caveats, the findings open an intriguing therapeutic window. If the vascular niche truly governs the regenerative failure of aging muscle, then interventions that boost angiogenesis — exercise training being the most proven, with hypoxic training, pneumatic compression, and gene therapy as research frontiers — might slow or partially reverse sarcopenia. And if larger, longitudinal, community-based studies confirm that a routine blood draw can flag failing muscle years before a fall, sarcopenia screening could shift from the grip dynamometer to the phlebotomy tray. For now, the message is measured but provocative: the health of aging muscles may be written, in part, in the chemistry of their blood supply.

Subject of Research: Associations between serum angiogenesis markers VEGF and ANGPT1 and sarcopenia in older adults

Article Title: Relationships between serum angiogenesis markers and sarcopenia: a cross-sectional study

Article References: Li, H., Liu, H., Liu, Y., Shi, W., Shi, L., & Jia, F. (2026). Relationships between serum angiogenesis markers and sarcopenia: a cross-sectional study. Frontiers in Medicine, 13, Article 1922045. https://doi.org/10.3389/fmed.2026.1922045

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1922045

Keywords: sarcopenia, angiogenesis, VEGF, ANGPT1, aging, muscle loss, blood vessels, biomarkers, geriatric medicine, cross-sectional study, hand grip strength, muscle regeneration

The chemical tags in question are methyl groups, small molecular attachments that bind to specific positions in the genome called CpG sites, where a cytosine nucleotide sits next to a guanine. DNA methylation is a classic epigenetic mark: it does not change the underlying genetic code, but it can dial gene activity up or down. Because the epigenome responds to environmental stimuli and physiological stress, the researchers reasoned that the massive injury caused by an aneurysm rupture might reshape methylation patterns in ways that influence the biological processes driving DCI, including vascular dysregulation, microthrombosis, cortical spreading depolarizations, and neuroinflammation. Previous candidate-gene studies had pointed to a handful of genes such as INSR, ITPR3, and HAMP, but genome-wide searches had been rare.

The team adopted a two-stage design that has become the gold standard in human genetics. In the discovery stage, they profiled methylation across roughly 450,000 CpG sites using the Illumina Infinium HumanMethylation450 BeadChip in blood samples drawn from 68 aSAH patients within 48 hours of their hemorrhage, before any sign of DCI. This timing matters: by collecting samples before the complication appeared, the investigators ensured that any methylation differences they found could not simply be a consequence of DCI itself. The patients, recruited through the University of Pittsburgh Medical Center Neurovascular Intensive Care Unit, had a mean age of 53.7 years, were predominantly female, and were followed for up to one year to track both DCI occurrence and long-term recovery using the Glasgow Outcome Scale and Modified Rankin Score.

The statistical machinery behind the discovery scan was deliberately rigorous. The researchers applied functional normalization to correct batch effects and technical noise, filtered out probes overlapping common genetic variants, sex chromosomes, and cross-reactive regions, and retained 418,247 CpG sites for analysis. They used M-values, which have more favorable statistical properties than raw beta values, and fitted linear models with empirical Bayes moderation while adjusting for age and sex. Crucially, they also incorporated surrogate variables derived from surrogate variable analysis to absorb the effects of cell-type heterogeneity, a notorious confounder in blood-based methylation studies, since different white blood cell populations carry distinct methylation signatures. The significance threshold for the epigenome-wide scan was set at a stringent 2.4 × 10⁻⁷.

No CpG site crossed that threshold. But the strongest signal in the entire scan landed at a site called cg18031596, annotated to a gene with an obvious biological connection to the disease process: ANGPT1, located on chromosome 8, which encodes angiopoietin-1, a protein central to blood vessel repair and stability. The p-value there was 2.3 × 10⁻⁶, and a post hoc power calculation showed the study had 94.6 percent power to detect a true difference of the observed magnitude. Angiopoietin-1 acts through the Tie2 receptor on endothelial cells, maintaining the integrity of the vascular lining, blocking leakage, and exerting anti-inflammatory effects. In mouse models, overexpression of the protein reduces ischemic lesion volume after arterial occlusion, and earlier clinical work had found that aSAH patients who later developed DCI showed decreased serum levels of angiopoietin-1 early after admission. All of this made ANGPT1 a compelling suspect.

To test the signal properly, the team turned to a replication cohort of 175 additional aSAH patients recruited under identical criteria at the same center. Rather than re-running the full array, they used targeted bisulfite pyrosequencing to measure methylation at five CpG sites across the ANGPT1 locus, including cg18031596 and four neighboring sites. Fifty-eight of the original discovery samples were re-assayed with the same sequencing method, bringing the combined dataset to 233 individuals, of whom 80 developed DCI. The sequencing measurements correlated well with the original array data, with Spearman coefficients ranging from 0.64 to 0.86, and the five targeted CpGs were highly correlated with one another, as expected for sites packed into a single regulatory region.

Then came the twist that gives this study its scientific drama. In the replication cohort, four of the five CpG sites were indeed significantly associated with DCI, passing the Bonferroni-adjusted threshold of 0.045. But the direction of the effects was flipped. In the discovery scan, higher methylation at cg18031596 had appeared to raise DCI risk; in the replication samples, higher methylation was associated with lower risk, with DCI cases showing a mean methylation of 4.84 percent versus 5.56 percent in controls. In the pooled analysis of all 233 patients, three of the five sites remained significant, and the strongest signal, at p = 0.004, came from a CpG that had not even been measured in the original array. By the strict logic of replication, the study failed: a consistent, reproducible effect of ANGPT1 methylation on DCI risk could not be demonstrated.

Rather than burying the inconsistency, the researchers dissected it with unusual transparency. They examined whether smoking, a known driver of methylation changes and a risk factor for aSAH, could explain the flip, but the pattern was messy, with some sites flipping only in smokers and others only in non-smokers. They tested whether the use of surrogate variables in the discovery stage, which could not be replicated in the smaller sequencing dataset, accounted for the discrepancy; this explained the sign reversal at four of the five sites but not at cg18031596 itself. They also noted that the two measurement technologies, array and pyrosequencing, though correlated, were not identical, leaving room for platform-specific artifacts. Finally, they ran a striking simulation: 10,000 random splits of the combined sample into discovery-sized and replication-sized groups. Among the 1,229 simulated discovery sets that produced a significant result, eight showed effect estimates as extreme as the real one, and in every one of those eight, the replication coefficient came out in the opposite direction. In other words, once a small discovery sample stumbles onto a chance extreme result, a direction-flipped replication is almost guaranteed, a phenomenon with a correlation of −0.87 between discovery and replication coefficients in the simulations.

The study also explored whether ANGPT1 methylation might predict recovery rather than DCI itself. In the discovery data, lower methylation at cg18031596 was associated with better Glasgow Outcome Scale scores at three months, with a borderline association at twelve months, and in the sequencing data higher methylation was linked to a lower risk of death at three months. None of these associations replicated cleanly, however, echoing a previous report that high serum angiopoietin-1 predicts better functional outcome. The authors caution that the relationship between methylation and gene expression is tissue-specific and dynamic, and it remains unknown whether methylation at cg18031596 actually regulates ANGPT1 expression in the relevant biological context, though public datasets suggest a correlation in several tissues.

The honest conclusion is that ANGPT1 methylation remains an open question rather than a validated biomarker. The study’s strengths include its longitudinal design, which rules out reverse causality, its careful control of technical artifacts and cell-type heterogeneity, and its willingness to publish a negative and confusing result in full detail, something the field needs more of. Its limitations are equally instructive: small samples inherent to a low-incidence, high-mortality disease, the inability to adjust for methylation quantitative trait loci without genotype data, and the open debate over whether blood is the right tissue for studying brain conditions, even though immune cells in blood do reflect the inflammatory responses implicated in DCI. For now, the message for patients and clinicians is that no epigenetic test can yet predict delayed cerebral ischemia after aneurysm rupture. But the study lays out a clear roadmap: larger, well-powered cohorts with complete genetic and clinical data are needed before ANGPT1, or any methylation marker, can move from statistical curiosity to bedside tool.

Subject of Research: DNA methylation at the ANGPT1 gene as a potential biomarker for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Article Title: ANGPT1 methylation and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients

Article References: Liu, D., Arockiaraj, A. I., Shaffer, J. R., Poloyac, S. M., Sherwood, P. R., Alexander, S. A., Crago, E. A., Weeks, D. E., & Conley, Y. P. (2021). ANGPT1 methylation and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients. Epigenetics Communications, 1(1), Article 3. https://doi.org/10.1186/s43682-021-00001-7

Image Credits: AI Generated

DOI: 10.1186/s43682-021-00001-7

Keywords: aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia, DNA methylation, ANGPT1, epigenome-wide association study, angiopoietin-1, biomarkers, neurocritical care, pyrosequencing, replication failure, surrogate variable analysis, stroke